Loading...
XASXIMM
Market cap308mUSD
Dec 23, Last price  
0.34AUD
1D
0.00%
1Q
0.00%
Jan 2017
-4.91%
Name

Immutep Ltd

Chart & Performance

D1W1MN
XASX:IMM chart
P/E
—
P/S
128.82
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
29.49%
Rev. gr., 5y
94.01%
Revenues
4m
+9.59%
00523,73401,520,0194,005,3943,140,0662,092,867175,0524,221,5342,630,484139,7827,486,4443,968,133170,3693,505,7223,841,877
Net income
-43m
L+7.07%
-1,887,356-2,946,356-12,158,848-21,081,095-19,940,960-15,225,671-13,343,381-32,151,696-62,015,184-9,367,206-12,746,020-16,270,641-13,468,232-29,902,624-32,210,826-39,896,348-42,716,625
CFO
-35m
L-2.96%
-1,554,336-1,883,470-6,461,680-9,755,703-19,120,369-16,037,126-14,227,161-7,786,982-11,309,691-8,506,798-7,776,703-15,286,398-10,839,339-17,640,342-30,229,752-35,883,000-34,821,229
Earnings
Feb 26, 2025

Profile

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
URL
https://www.immutep.com/
IPO date
Jun 23, 1988
Employees
19
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
3,842
9.59%
3,506
1,957.72%
170
-95.71%
Cost of revenue
91,946
44,937
40,615
Unusual Expense (Income)
NOPBT
(88,104)
(41,431)
(40,445)
NOPBT Margin
Operating Taxes
2
34
Tax Rate
NOPAT
(88,104)
(41,431)
(40,445)
Net income
(42,717)
7.07%
(39,896)
23.86%
(32,211)
7.72%
Dividends
Dividend yield
Proceeds from repurchase of equity
100,236
80,083
52,975
BB yield
-28.29%
-28.23%
-21.18%
Debt
Debt current
234
185
173
Long-term debt
1,993
1,436
1,841
Deferred revenue
Other long-term liabilities
211
164
(2,964)
Net debt
(179,650)
(121,797)
(77,980)
Cash flow
Cash from operating activities
(34,821)
(35,883)
(30,230)
CAPEX
(932)
(47)
(23)
Cash from investing activities
(21,019)
(31)
(23)
Cash from financing activities
95,180
76,042
50,326
FCF
(86,355)
(37,869)
(42,968)
Balance
Cash
181,876
123,418
79,995
Long term investments
Excess cash
181,684
123,242
79,987
Stockholders' equity
189,522
136,469
94,077
Invested Capital
9,642
14,620
45,072
ROIC
ROCE
EV
Common stock shares outstanding
1,201,062
900,641
862,338
Price
0.30
-6.35%
0.32
8.62%
0.29
-47.27%
Market cap
354,313
24.89%
283,702
13.45%
250,078
-24.76%
EV
174,664
161,905
172,097
EBITDA
(85,842)
(39,369)
(38,381)
EV/EBITDA
Interest
31
20
92
Interest/NOPBT